Apollon/Wyeth-Ayerst DNA vaccine collaboration

6 November 1995

- Apollon and Wyeth-Ayerst are jointly developing and commercializing a Genevax DNA vaccine technology with potential uses against a variety of diseases. Initial targets are HIV, herpes simplex and human papilloma virus. Under the terms of the multi-year deal, any products resulting from the project will be made by Apollon and sold exclusively to Wyeth-Ayerst for distribution. Milestone payments to Apollon could exceed $100 million, the firms said. The Genevax technology combines DNA with chemicals that encourage host cells to absorb antigenic material; expression of the foreign DNA in turn stimulates an appropriate immune response.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight